Cracking Cancer Metastasis: Targeting the Tumor Microenvironment and Immune Evasion Immunotherapy, particularly immune checkpoint blockade (ICB), has undeniably revolutionized the landscape of oncology. By harnessing the body's own immune system, therapies targeting PD-1/PD-L1 and CTLA-4 have achieved unprecedented durable responses in patients. However, a significant clinical challenge remains: a large cohort of patients experiences primary or acquired resistance, and tumor...
English